Researchers confirm the safety of Oxford-AstraZeneca COVID-19 vaccine
Category: #headlines |   By Hrishikesh Kadam |   Date: 2020-12-10  | 
  • Share
  • Twitter
  • Facebook
  • LinkedIn

Researchers confirm the safety of Oxford-AstraZeneca COVID-19 vaccine

Researchers have reportedly confirmed the safety and efficacy of the Oxford/AstraZeneca COVID-19 vaccine in a study published in the Lancet journal. Even though most people in the study were aged less than 55, it has been found that the vaccine works well in older people as well. The vaccine is further speculated to assist in the reduction of the spread of COVID-19 as well as in offering protection against the disease and death.

According to AstraZeneca’s CEO, Pascal Soriot, the results of the study demonstrate the effectiveness of the vaccine against COVID-19, with no hospitalizations and no severe infections found in the vaccine group. Soriot has further highlighted that with the vaccine being well tolerated and safe, the company has begun the submission of data to regulatory authorities across the world for obtaining early approval.

The company’s worldwide supply chains are up and running, all set for the quick commencement of the delivery of hundreds of millions of doses at no profit at the global level, added the CEO.

Out of thousands of people involved in the trial, around 1,367 people were given the half dose followed by a full dose, which provided them with 90 per cent protection against falling ill with COVID-19. The presence of a comparatively small number in this group, however, signifies that it is difficult to draw firm conclusions as none of the members of the group were above 55 and experts know that it is older people who are the most vulnerable to severe SARS-CoV-2 illness.

Expressing his opinion over the publication of the study, Wellcome’s Head of Vaccines, Dr. Charlie Weller, mentioned that the study marks another significant milestone in the COVID-19 journey. Weller further stated that, even though Wellcome awaits full data and trial completion, it is extremely encouraging to witness that the data behind the interim results, announced in the previous month, comprised an analysis of the various dosing regimens. This suggests the capability of the vaccine to prevent the spread of the asymptomatic disease, added Weller.

Source credit: https://www.bbc.com/news/health-55228422

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Hrishikesh Kadam    

Hrishikesh Kadam

A graduate in electronics and telecommunication engineering, Hrishikesh Kadam has always found writing fascinating. Driven by a never-ending passion for content creation combined with a bit of experience in writing personal blogs, Hrishikesh blends his technical knowl...

Read More

More News By Hrishikesh Kadam

OneWeb raises USD 1.4 billion; Hughes and SoftBank lead investors
OneWeb raises USD 1.4 billion; Hughes and SoftBank lead investors
By Hrishikesh Kadam

According to reliable sources, London-based multinational broadband satellite operator OneWeb has reportedly raised USD 1.4 billion in a funding round led by Hughes Network Systems LLC and SoftBank Group Corporation. The fresh investments will allow ...

Atos to strengthen its cybersecurity footprint through In Fidem buyout
Atos to strengthen its cybersecurity footprint through In Fidem buyout
By Hrishikesh Kadam

French multinational information technology company Atos has reportedly finalized an agreement to acquire In Fidem, a Quebec-based cybersecurity specialist. According to reliable sources, In Fidem’s acquisition will allow Atos to strengthen its...

Milestone acquires Covestic to boost IT managed services portfolio
Milestone acquires Covestic to boost IT managed services portfolio
By Hrishikesh Kadam

Milestone Technologies, an IT service management company, has recently announced the acquisition of the U.S.-based IT professional services company, Covestic, LLC. The deal was geared towards the expansion of the company’s regional footprint in...